0001104659-21-065032.txt : 20210615 0001104659-21-065032.hdr.sgml : 20210615 20210512135444 ACCESSION NUMBER: 0001104659-21-065032 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 CORRESP 1 filename1.htm

May 12, 2021

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Mail Stop 4546

Washington, D.C. 20549

Attn:

Jane Park

Re:	Chemomab Therapeutics Ltd.
	Registration Statement on Form S-3
	Filed April 30, 2021
	File No. 333-255658

Acceleration Request

Requested Date: May 17, 2021

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-255658) (the “Registration Statement”), to become effective on May 17, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the Commission’s staff.

It would be appreciated if, promptly after the Registration Statement has become effective, you would so confirm that event with our outside counsel, Mr. David S. Glatt of Meitar | Law Offices, by email at dglatt@meitar.com. The Company hereby authorizes Mr. Glatt to orally modify or withdraw this request for acceleration.

[Signature page follows]

	Very truly yours,

	Chemomab Therapeutics Ltd.

	By:	/s/ Sigal Fattal

	Sigal Fattal
	Chief Financial Officer

cc:	Sigal Fattal, Chemomab Therapeutics Ltd.
	David S. Glatt, Adv., Meitar \| Law Offices